Published in Cell on May 01, 1998
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Myeloproliferative disorders. Blood (2008) 3.37
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol (2003) 2.93
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev (2008) 2.68
Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes Dev (2005) 2.63
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway. Genes Dev (1998) 2.47
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov (2011) 2.38
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol (2000) 2.25
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
The Janus kinases (Jaks). Genome Biol (2004) 2.18
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood (2005) 2.17
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood (2010) 2.16
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood (2006) 2.16
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J (1999) 2.10
Therapeutic targeting of Janus kinases. Immunol Rev (2008) 2.03
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood (2008) 2.01
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med (2004) 1.98
Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96
Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine (2008) 1.95
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol (2009) 1.92
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol (2002) 1.92
Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A (1998) 1.90
Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest (2008) 1.89
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood (2011) 1.84
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell (2003) 1.79
Identification of SH2-bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc Natl Acad Sci U S A (1999) 1.79
Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol (2008) 1.79
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) (2010) 1.78
Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol (2004) 1.78
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood (2014) 1.68
The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J (2001) 1.67
The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol (2001) 1.65
Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol (2004) 1.64
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol (2004) 1.55
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood (2014) 1.55
Series introduction. JAK-STAT signaling in human disease. J Clin Invest (2002) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol (2008) 1.48
Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol (2004) 1.43
Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med (2008) 1.36
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol (2007) 1.34
Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J (1999) 1.33
Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood (2008) 1.31
Biology and significance of the JAK/STAT signalling pathways. Growth Factors (2012) 1.29
SH2-B is required for both male and female reproduction. Mol Cell Biol (2002) 1.27
STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest (2007) 1.27
EPO receptor circuits for primary erythroblast survival. Blood (2008) 1.26
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev (1998) 1.24
The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. Mol Cell Biol (2000) 1.23
Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene (2006) 1.22
Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol (2008) 1.21
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood (2010) 1.21
Aberrant cytokine signaling in leukemia. Oncogene (2007) 1.20
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood (2008) 1.20
JAK2/STAT2/STAT3 are required for myogenic differentiation. J Biol Chem (2008) 1.17
Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest (2011) 1.17
Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol Cell Biol (2006) 1.16
Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis (2004) 1.16
Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest (2000) 1.12
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J (2006) 1.11
Identification, cDNA cloning, and targeted deletion of p70, a novel, ubiquitously expressed SH3 domain-containing protein. Mol Cell Biol (2002) 1.10
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol (2009) 1.10
A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1. PLoS Genet (2011) 1.09
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. PLoS One (2010) 1.07
Signals emanating from the membrane proximal region of the thrombopoietin receptor (mpl) support hematopoietic stem cell self-renewal. Exp Hematol (2007) 1.07
Erythropoietin receptor response circuits. Curr Opin Hematol (2010) 1.07
Murine macrophage transcriptional responses to Bacillus anthracis infection and intoxication. Infect Immun (2005) 1.06
Genome-wide expression profiling in the Drosophila eye reveals unexpected repression of notch signaling by the JAK/STAT pathway. Dev Dyn (2009) 1.06
Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol (2014) 1.05
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A (2014) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett (2009) 1.04
A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem (2009) 1.03
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS One (2013) 1.03
Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. J Biol Chem (2008) 1.02
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia (2013) 1.01
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum (2012) 1.01
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol Cancer Ther (2008) 1.00
Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells. J Virol (2010) 1.00
Src family kinases are required for prolactin induction of cell proliferation. Mol Biol Cell (2001) 0.99
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Sequence of the gene for the constant region of the mu chain of Balb/c mouse immunoglobulin. Gene (1981) 8.45
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell (1984) 6.78
The genome of the sea urchin Strongylocentrotus purpuratus. Science (2006) 6.41
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 6.17
ZnO nanowire UV photodetectors with high internal gain. Nano Lett (2007) 6.06
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell (1993) 6.04
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 5.95
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (1996) 5.45
High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice. Proc Natl Acad Sci U S A (2007) 5.42
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet (1999) 4.79
The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J (1997) 4.65
Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc (2001) 4.46
The developmental biochemistry of cottonseed embryogenesis and germination. 3. Regulation of the biosynthesis of enzymes utilized in germination. J Biol Chem (1972) 4.41
Processed pseudogenes: characteristics and evolution. Annu Rev Genet (1985) 4.40
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (1984) 4.30
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature (1993) 4.20
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Structural organization of the bcr gene and its role in the Ph' translocation. Nature (1985) 4.08
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell (1993) 4.06
Hormonal regulation of translation inhibition requiring RNA synthesis. Biochem Biophys Res Commun (1970) 4.01
Procedures for the purification of interleukin 3 to homogeneity. J Immunol (1982) 3.96
Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ (2006) 3.95
Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A (1987) 3.92
Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev (1997) 3.88
Comparison of cloned rabbit and mouse beta-globin genes showing strong evolutionary divergence of two homologous pairs of introns. Nature (1978) 3.86
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell (1988) 3.75
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
Unexpected relationships between four large deletions in the human beta-globin gene cluster. Cell (1983) 3.57
Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell (1993) 3.54
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 3.53
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature (1994) 3.36
Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol (2001) 3.25
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1984) 3.24
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol (1992) 3.12
Tumor spectrum in ARF-deficient mice. Cancer Res (1999) 3.11
Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity (2000) 3.06
Defective lymphoid development in mice lacking Jak3. Science (1995) 3.04
Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol (1992) 2.99
A mouse alpha-globin-related pseudogene lacking intervening sequences. Nature (1980) 2.92
Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A (1993) 2.88
Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus. Proc Natl Acad Sci U S A (1978) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol (1999) 2.82
A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron (1999) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology (2008) 2.79
Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation (1996) 2.77
Ecology. Giant pandas in a changing landscape. Science (2001) 2.73
Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem (2000) 2.70
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Neoplastic transformation of mast cells by Abelson-MuLV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell (1985) 2.59
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol (1994) 2.55
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity (2000) 2.54
Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol (1997) 2.51
Translocation of oncogene c-sis from chromosome 22 to chromosome 11 in a Ewing sarcoma-derived cell line. Mol Cell Biol (1985) 2.45
Regional mapping of the human immunoglobulin lambda light chain to the Philadelphia chromosome in chronic myeloid leukaemia. Leuk Res (1984) 2.44
B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell (1987) 2.44
Truncation of the c-myb gene by a retroviral integration in an interleukin 3-dependent myeloid leukemia cell line. Proc Natl Acad Sci U S A (1986) 2.43
RAE1 is a shuttling mRNA export factor that binds to a GLEBS-like NUP98 motif at the nuclear pore complex through multiple domains. J Cell Biol (1999) 2.42
Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol (1992) 2.41
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
Self-rated health and survival: a 7-year follow-up study of Australian elderly. Am J Public Health (1994) 2.37
Autogenous immunity to endogenous RNA tumor virus. Radioimmune precipitation assay of mouse serum antibody levels. J Exp Med (1973) 2.31
Cre-mediated site-specific translocation between nonhomologous mouse chromosomes. Proc Natl Acad Sci U S A (1995) 2.29
The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J Neurosci (2000) 2.28
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell (1987) 2.27
The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol (2000) 2.26
Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem (1998) 2.26
Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials (2000) 2.24
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol (1982) 2.22